44 completed. 44 Phase 2, 5 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 44 | Completed 44 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 4 | Completed 4 |
Follow Urogenital Abnormalities: new trials by email Literature Review of Urogenital Abnormalities trials Research Report on Urogenital Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1) Vonafexor - Alport Syndrome | Phase 2 | Completed | Enyo Pharma | 26 | 2024-08-01 | 2026-02-09 |
| A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity Bivamelagon, Placebo - Hypothalamic Obesity | Phase 2 | Completed | Rhythm Pharmaceuticals, Inc. | 28 | 2024-07-11 | 2026-10-30 |
| A Study to Evaluate Setanaxib in Patients With Alport Syndrome Setanaxib, Placebo - Alport Syndrome | Phase 1 / Phase 2 | Completed | Calliditas Therapeutics AB | 20 | 2023-11-27 | 2026-04-13 |
| Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn) atumelnant (CRN04894) - Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 38 | 2023-07-03 | 2026-09-10 |
| A Study of ELX-02 in Patients With Alport Syndrome ELX-02 - Alport Syndrome | Phase 2 | Completed | Eloxx Pharmaceuticals, Inc. | 3 | 2022-11-28 | 2026-02-24 |
| Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis R3R01 - Alport Syndrome, Focal Segmental Glomerulosclerosis | Phase 2 | Completed | River 3 Renal Corp. | 43 | 2022-06-15 | 2025-09-29 |
| A Trial of YPEG-rhGH in Children With Short Stature YPEG-rhGH, rhGH - Idiopathic Short Stature, Small for Gestational Age | Phase 2 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 78 | 2022-02-15 | 2024-01-24 |
| Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS) Hydroxychloroquine Sulfate 100 milligram (mg) Tab, Benazepril hydrochloride 10 milligram (mg) Tab - Alport Syndrome, X-Linked | Phase 2 | Completed | Shanghai Children's Hospital | 50 | 2021-09-08 | 2026-03-02 |
| Open-Label Study of Setmelanotide in Hypothalamic Obesity Setmelanotide - Hypothalamic Obesity | Phase 2 | Completed | Rhythm Pharmaceuticals, Inc. | 18 | 2021-06-07 | 2025-02-07 |
| Inositol Supplementation to Treat PCOS (INSUPP-PCOS) Placebo, Inositol - Polycystic Ovary Syndrome, Anovulation | Phase 2 | Completed | Milton S. Hershey Medical Center | 154 | 2020-01-24 | 2026-10-28 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia Crinecerfont - CAH - Congenital Adrenal Hyperplasia | Phase 2 | Completed | Neurocrine Biosciences | 8 | 2019-12-12 | 2024-07-18 |
| Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction Salsalate, Placebo - Polycystic Ovary Syndrome | Phase 2 | Completed | University of Illinois at Chicago | 60 | 2018-12-05 | 2025-06-10 |
| Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia SPR001 - Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia | Phase 2 | Completed | Spruce Biosciences | 11 | 2018-09-06 | 2025-04-01 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia NBI-74788 - CAH - Congenital Adrenal Hyperplasia | Phase 2 | Completed | Neurocrine Biosciences | 18 | 2018-04-10 | 2022-05-03 |
| Modified Second Layer Repair for Distal Penile Hypospadias Derma -Dartos Flap for second layer closure - Hypospadias | Phase 2 | Completed | Ain Shams University | 102 | 2018-03-01 | 2022-02-23 |
| Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome LIK066, Placebo - Polycystic Ovary Syndrome | Phase 2 | Completed | Novartis Pharmaceuticals | 29 | 2017-07-24 | 2021-01-05 |
| Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia SPR001 - Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia | Phase 2 | Completed | Spruce Biosciences | 24 | 2017-07-12 | 2025-10-22 |
| A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL Placebo Oral Capsule, Bardoxolone Methyl - Alport Syndrome | Phase 2 / Phase 3 | Completed | Biogen | 187 | 2017-03-02 | 2025-06-11 |
| Isoamyl 2-Cyanoacrylate in the Urethro-cutaneous Fistula Repair Cyanoacrylate, Isobutyl, Classic surgical repair - Hypospadias | Phase 2 / Phase 3 | Completed | Ain Shams University | 40 | 2017-01-01 | 2021-05-07 |
| Intranasal Oxytocin in Hypothalamic Obesity Syntocinon, Placebo (for Syntocinon) - Craniopharyngioma, Hypothalamic Obesity | Phase 2 | Completed | Shana McCormack, MD | 18 | 2016-10-01 | 2022-10-05 |
Showing 20 of 44. Sign in to see all of them.
Adrenal Hyperplasia, Congenital (12) · Nephritis, Hereditary (7) · Hyperandrogenism (6) · Sexual Infantilism (6) · Turner Syndrome (6) · Polycystic Ovary Syndrome (4) · Anovulation (3) · Craniopharyngioma (3) · Hypospadias (3) · Insulin Resistance (3) · Klinefelter Syndrome (3) · Adrenal Insufficiency (2) · Congenital adrenal hyperplasia due to 21 hydroxylase deficiency (2) · Dwarfism (2) · Endocrine System Diseases (2)
Congenital Abnormalities (44) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (44) · Male Urogenital Diseases (44) · Urogenital Diseases (44) · Female Urogenital Diseases (43) · Female Urogenital Diseases and Pregnancy Complications (43) · Gonadal Disorders (34) · Disorders of Sex Development (32) · Endocrine System Diseases (32) · Genetic Diseases, Inborn (20) · Nutritional and Metabolic Diseases (17) · Adrenogenital Syndrome (16) · Metabolic Diseases (16) · Adrenal Gland Diseases (12)
Hydrocortisone (4) · Exenatide (2) · Growth Hormone (2) · Human Growth Hormone (2) · Oxandrolone (2) · benazepril (2) · crinecerfont (2) · Anesthesia, General (1) · Atropine (1) · Bucrylate (1) · Bupivacaine (1) · Calcitriol (1) · Calcium Dobesilate (1) · Castor Oil (1) · Dexamethasone (1)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (4) · Ain Shams University (2) · National Center for Research Resources (NCRR) (2) · Neurocrine Biosciences (2) · Neurocrine UK Limited (2) · Novartis Pharmaceuticals (2) · Rhythm Pharmaceuticals, Inc. (2) · Spruce Biosciences (2) · Biogen (1) · Boston Children's Hospital (1) · Calliditas Therapeutics AB (1) · Children's Hospitals and Clinics of Minnesota (1) · Crinetics Pharmaceuticals Inc. (1) · Eloxx Pharmaceuticals, Inc. (1) · Enyo Pharma (1)
United States (31) · United Kingdom (6) · France (5) · China (4) · Germany (4) · Italy (3) · Spain (3) · Australia (2) · Egypt (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1)
David Meeker, MD (2) · Andrea Isidori, MD, PhD (1) · Andrea Lenzi, MD (1) · Ashley Shoemaker, M.D. (1) · Daniel Dumesic, MD (1) · Deborah P Merke, BS, MS, MD (1) · Deborah P Merke, M.D. (1) · Erica Daina, MD (1) · Jill Hamilton, MD (1) · Jin Liu, M.D. (1)
PMID 40938675, PMID 34146101, PMID 20871859, PMID 21449786, PMID 24762109, PMID 25494662, PMID 27133664, PMID 27637014, PMID 27680873, PMID 28285751, PMID 29931143, PMID 30003563, PMID 30302881, PMID 31532522, PMID 32589738, PMID 33159213, PMID 33789284, PMID 34433653, PMID 36400597, PMID 36411058, PMID 37172949, PMID 37216921, PMID 38724717
2015 (1), 2017 (1), 2023 (1), M01RR001070 (1), R01AT009484 (1), R01DK107605 (1)